发布求助
文献互助 智能选刊 最新文献

Blood Cancer Discovery最新文献

筛选
英文 中文
SOCS1 protects acute myeloid leukemia against allogeneic T cell-mediated cytotoxicity. SOCS1 可保护急性髓性白血病免受异体 T 细胞介导的细胞毒性的影响。
IF 11.5
Blood Cancer Discovery Pub Date : 2025-02-10 DOI: 10.1158/2643-3230.BCD-24-0140
Enoch Tin, Sergio Rutella, Ismat Khatri, Yoosu Na, Yongran Yan, Neil MacLean, Jayakumar Vadakekolathu, Mark D Minden, Aaron D Schimmer, JongBok Lee, Li Zhang
{"title":"SOCS1 protects acute myeloid leukemia against allogeneic T cell-mediated cytotoxicity.","authors":"Enoch Tin, Sergio Rutella, Ismat Khatri, Yoosu Na, Yongran Yan, Neil MacLean, Jayakumar Vadakekolathu, Mark D Minden, Aaron D Schimmer, JongBok Lee, Li Zhang","doi":"10.1158/2643-3230.BCD-24-0140","DOIUrl":"https://doi.org/10.1158/2643-3230.BCD-24-0140","url":null,"abstract":"<p><p>Despite the curative potential of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia (AML), its efficacy is limited by intrinsic resistance of cancer cells to donor-derived T-cell cytotoxicity. Using a genome-wide CRISPR screen, we identified the SOCS1-JAK1-STAT1 pathway as a mediator of AML susceptibility to T cells. SOCS1 knockdown in AML cells sensitized them to killing by allogeneic T cells, whereas SOCS1 overexpression in AML cells induced resistance to T-cell anti-leukemic activity. Mechanistically, SOCS1 protected AML cells from T-cell killing by antagonizing IFNγ-JAK1-induced ICAM-1 expression. Furthermore, primary AML cells with lower SOCS1 expression correlated with better overall survival in patients, especially those with a lower exhausted CD8+ T-cell score. Thus, this study reveals SOCS1 and its downstream mediators as a potential targetable pathway to enhance T cell-based immunotherapy for AML.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":""},"PeriodicalIF":11.5,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-dose methotrexate, ibrutinib, and temozolomide in the treatment of newly diagnosed primary CNS lymphoma: a multicenter, prospective phase-II study.
IF 11.5
Blood Cancer Discovery Pub Date : 2025-02-06 DOI: 10.1158/2643-3230.BCD-24-0156
Yan Gao, Liqin Ping, Changguo Shan, He Huang, Zhiming Li, Hui Zhou, Mingyao Lai, Linbo Cai, Bing Bai, Cheng Huang, Haoqing Chen, Xiaoyu Hong, Xiaoxiao Wang, Huiqiang Huang
{"title":"High-dose methotrexate, ibrutinib, and temozolomide in the treatment of newly diagnosed primary CNS lymphoma: a multicenter, prospective phase-II study.","authors":"Yan Gao, Liqin Ping, Changguo Shan, He Huang, Zhiming Li, Hui Zhou, Mingyao Lai, Linbo Cai, Bing Bai, Cheng Huang, Haoqing Chen, Xiaoyu Hong, Xiaoxiao Wang, Huiqiang Huang","doi":"10.1158/2643-3230.BCD-24-0156","DOIUrl":"https://doi.org/10.1158/2643-3230.BCD-24-0156","url":null,"abstract":"<p><p>Genetic alterations of chronic active B-cell receptor signaling often occur in primary central nervous system lymphoma (PCNSL). We conducted a phase-II trial of high-dose methotrexate plus ibrutinib and temozolomide (MIT) in the treatment of newly diagnosed PCNSL. A total of 35 patients were enrolled, with 33 patients included in the analysis. The best overall response rate was 93.9% and complete response rate was 72.7% for induction therapy. The 2-year progression-free survival (PFS) and overall survival were 57.6% (95%CI: 49.0-66.2) and 84.8% (95%CI: 78.6-91.0). The incidence of grade ≧ 3 adverse events was 27.3% (10/33). Mutations in PIM1, MYD88, BTG2, and CD79B were most frequent among 475 genes tested by targeted sequencing of tumor and CSF samples at baseline. The consistency of ctDNA clearance from CSF/plasma and complete response on imaging were observed. Patients with clearance of ctDNA from CSF after two cycles achieved longer PFS (p = 0.044).</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":""},"PeriodicalIF":11.5,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143256865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma.
IF 11.5
Blood Cancer Discovery Pub Date : 2025-02-06 DOI: 10.1158/2643-3230.BCD-24-0178
Nora Liebers, Ariane Boumendil, Hervé Finel, Dominic Edelmann, Guido Kobbe, Ben-Niklas Baermann, Yasmina Serroukh, Didier Blaise, Dietrich Wilhelm Beelen, Carlos Solano, Maija Itälä-Remes, Tom van Meerten, Goda Choi, Susanne A C Schmidt, Nicolaus Kröger, Jenny Byrne, Jean-Jacques Tudesq, Anna Ossami Saidy, Ana Nunes, Rubina Siddiqi, Elande Baro, Dan Zheng, Ioana Kloos, Peter Dreger, Anna Sureda, Bertram Glass, Sascha Dietrich
{"title":"Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma.","authors":"Nora Liebers, Ariane Boumendil, Hervé Finel, Dominic Edelmann, Guido Kobbe, Ben-Niklas Baermann, Yasmina Serroukh, Didier Blaise, Dietrich Wilhelm Beelen, Carlos Solano, Maija Itälä-Remes, Tom van Meerten, Goda Choi, Susanne A C Schmidt, Nicolaus Kröger, Jenny Byrne, Jean-Jacques Tudesq, Anna Ossami Saidy, Ana Nunes, Rubina Siddiqi, Elande Baro, Dan Zheng, Ioana Kloos, Peter Dreger, Anna Sureda, Bertram Glass, Sascha Dietrich","doi":"10.1158/2643-3230.BCD-24-0178","DOIUrl":"https://doi.org/10.1158/2643-3230.BCD-24-0178","url":null,"abstract":"<p><p>Brexucabtagene autoleucel (brexu-cel) and allogeneic hematopoietic cell transplantation (alloHCT) are effective treatments for relapsed or refractory mantle cell lymphoma (r/r MCL), but the optimal choice remains unclear. We conducted an analysis of 64 r/r MCL patients aged ≥50 years treated with brexu-cel in the ZUMA-2 study, matching them 1:1 by propensity score to 64 (out of 272) r/r MCL patients who underwent alloHCT using data from the EBMT registry. Median follow-up time was 36.5 and 34.1 months for the brexu-cel and matched alloHCT cohort, respectively. Brexu-cel patients had a significantly higher overall survival (OS, 81.3% vs 59.2%, HR: 0.39, p=0.004) and lower non-relapse mortality (3.6% vs 21.2%, p=0.015) one year after treatment. Chronic graft-vs-host disease occurred in 26.9% of alloHCT patients within the first year. However, long-term progression-free survival and OS remain comparable. Despite limitations of this non-randomized study, it indicates a superior safety profile for brexu-cel in r/r MCL.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":""},"PeriodicalIF":11.5,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143365781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia. 基于 Venetoclax 的急性髓性白血病联合疗法
IF 11.5
Blood Cancer Discovery Pub Date : 2025-01-08 DOI: 10.1158/2643-3230.BCD-24-0171
Hannah Goulart, Hagop Kantarjian, Naveen Pemmaraju, Naval Daver, Courtney D DiNardo, Caitlin R Rausch, Farhad Ravandi, Tapan M Kadia
{"title":"Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia.","authors":"Hannah Goulart, Hagop Kantarjian, Naveen Pemmaraju, Naval Daver, Courtney D DiNardo, Caitlin R Rausch, Farhad Ravandi, Tapan M Kadia","doi":"10.1158/2643-3230.BCD-24-0171","DOIUrl":"10.1158/2643-3230.BCD-24-0171","url":null,"abstract":"<p><strong>Significance: </strong>In recent years, there has been tremendous interest surrounding the integration of venetoclax into both non-intensive and intensive chemotherapy regimens for AML. However, with this increasing utilization of venetoclax, considerable questions surrounding key issues such as dosing strategies and the practicality of venetoclax administration have arisen. This review highlights the evolution of venetoclax-based regimens in AML and provides a commentary on notable practical considerations when utilizing this agent.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"23-37"},"PeriodicalIF":11.5,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142677230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Total (Immuno)Therapy: Version 2.0. 全面（免疫）疗法》：2.0 版。
IF 11.5
Blood Cancer Discovery Pub Date : 2025-01-08 DOI: 10.1158/2643-3230.BCD-24-0236
Susan Bal, Luciano J Costa
{"title":"Total (Immuno)Therapy: Version 2.0.","authors":"Susan Bal, Luciano J Costa","doi":"10.1158/2643-3230.BCD-24-0236","DOIUrl":"10.1158/2643-3230.BCD-24-0236","url":null,"abstract":"<p><p>Among patients with poly-refractory myeloma, autologous chimeric antigen receptor T-cell therapy offers exceptional promise. With the availability of bispecific antibodies, a total immunotherapeutic strategy in combination with chimeric antigen receptor T-cell therapy is now feasible. See related article by Fandrei et al., p. 38.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"10-12"},"PeriodicalIF":11.5,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142717284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A Roadmap. 最小残留病作为加速骨髓瘤药物审批的早期终点：路线图
IF 11.5
Blood Cancer Discovery Pub Date : 2025-01-08 DOI: 10.1158/2643-3230.BCD-24-0292
Ola Landgren, Sean M Devlin
{"title":"Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A Roadmap.","authors":"Ola Landgren, Sean M Devlin","doi":"10.1158/2643-3230.BCD-24-0292","DOIUrl":"10.1158/2643-3230.BCD-24-0292","url":null,"abstract":"<p><strong>Significance: </strong>The acceptance of MRD-negative complete response as an endpoint that is reasonably likely to predict clinical benefit will allow for the design of streamlined clinical trials for accelerated approval, enabling significantly faster patient access to novel therapies. Cooperative efforts were required to obtain and analyze clinical trial data from multiple sponsors and to determine the best approach to analysis with a relatively limited number of available datasets. The process to evaluate MRD as an intermediate endpoint, undertaken jointly by myeloma researchers and industry, with feedback from the FDA, serves as a roadmap for other areas of oncology to develop intermediate endpoints.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"13-22"},"PeriodicalIF":11.5,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142781205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CD33-CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells. CD33-CD123 IF-THEN门控降低毒性，同时增强aml靶向CAR-T细胞的特异性和记忆表型。
IF 11.5
Blood Cancer Discovery Pub Date : 2025-01-08 DOI: 10.1158/2643-3230.BCD-23-0258
Samy Jambon, Jianping Sun, Shawn Barman, Sakunthala Muthugounder, Xue Rachel Bito, Armita Shadfar, Alexandra E Kovach, Brent L Wood, Varsha Thoppey Manoharan, A Sorana Morrissy, Deepa Bhojwani, Alan S Wayne, Michael A Pulsipher, Yong-Mi Kim, Shahab Asgharzadeh, Chintan Parekh, Babak Moghimi
{"title":"CD33-CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells.","authors":"Samy Jambon, Jianping Sun, Shawn Barman, Sakunthala Muthugounder, Xue Rachel Bito, Armita Shadfar, Alexandra E Kovach, Brent L Wood, Varsha Thoppey Manoharan, A Sorana Morrissy, Deepa Bhojwani, Alan S Wayne, Michael A Pulsipher, Yong-Mi Kim, Shahab Asgharzadeh, Chintan Parekh, Babak Moghimi","doi":"10.1158/2643-3230.BCD-23-0258","DOIUrl":"10.1158/2643-3230.BCD-23-0258","url":null,"abstract":"<p><strong>Significance: </strong>Our study demonstrates the use of \"IF-THEN\" SynNotch-gated CAR-T cells targeting CD33 and CD123 in AML reduces off-tumor toxicity. This strategy enhances T-cell phenotype, improves expansion, preserves HSPCs, and mitigates cytokine release syndrome-addressing critical limitations of existing AML CAR-T therapies.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"55-72"},"PeriodicalIF":11.5,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707512/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma. 双特异性抗体是治疗复发/难治性多发性骨髓瘤的 BCMA CAR-T 细胞疗法的桥梁。
IF 11.5
Blood Cancer Discovery Pub Date : 2025-01-08 DOI: 10.1158/2643-3230.BCD-24-0118
David Fandrei, Sabine Seiffert, Michael Rade, Susanne Rieprecht, Nico Gagelmann, Patrick Born, Thomas Wiemers, Heike Weidner, Markus Kreuz, Tamara Schassberger, Jannik Koßmann, Marlene Mangold, Daniel Fürst, Luise Fischer, Ronny Baber, Simone Heyn, Song Yau Wang, Enrica Bach, Sandra Hoffmann, Klaus H Metzeler, Marco Herling, Madlen Jentzsch, Georg-Nikolaus Franke, Ulrike Köhl, Maik Friedrich, Andreas Boldt, Kristin Reiche, Uwe Platzbecker, Vladan Vucinic, Maximilian Merz
{"title":"Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma.","authors":"David Fandrei, Sabine Seiffert, Michael Rade, Susanne Rieprecht, Nico Gagelmann, Patrick Born, Thomas Wiemers, Heike Weidner, Markus Kreuz, Tamara Schassberger, Jannik Koßmann, Marlene Mangold, Daniel Fürst, Luise Fischer, Ronny Baber, Simone Heyn, Song Yau Wang, Enrica Bach, Sandra Hoffmann, Klaus H Metzeler, Marco Herling, Madlen Jentzsch, Georg-Nikolaus Franke, Ulrike Köhl, Maik Friedrich, Andreas Boldt, Kristin Reiche, Uwe Platzbecker, Vladan Vucinic, Maximilian Merz","doi":"10.1158/2643-3230.BCD-24-0118","DOIUrl":"10.1158/2643-3230.BCD-24-0118","url":null,"abstract":"<p><p>Establishing a strategy for sequencing of T cell-redirecting therapies for relapsed/refractory multiple myeloma (RRMM) is a pressing clinical need. We longitudinally tracked the clinical and immunologic impact of bispecific T cell-engaging antibodies (BsAb) as bridging therapy (BT) to subsequent B-cell maturation antigen-directed chimeric antigen receptor T (CAR-T) cell therapies in 52 patients with RRMM. BsAbs were a potent and safe option for BT, achieving the highest overall response rate (100%) to BT compared with chemotherapy, anti-CD38, or anti-SLAMF7 antibody-based regimens (46%). We observed early CD4+CAR+ and delayed CD8+CAR+ T-cell expansion in patients receiving BsAbs as BT. In vitro cytotoxicity of CAR-T cells was comparable among BT options. Single-cell analyses revealed increased clonality in the CD4+ and CD8+ T-cell compartments in patients with previous exposure to BsAbs at leukapheresis and on day 30 after CAR-T cell infusion. This study demonstrates the feasibility and efficacy of BT with BsAbs for CAR-T cell therapy in RRMM. Significance: CAR-T cell therapy and BsAbs have revolutionized treatment of triple-class refractory multiple myeloma; however, optimal sequencing is unknown. We demonstrate that BT with BsAb before B-cell maturation antigen-directed CAR-T cell therapy is safe and effective, which might have implications for other hematologic malignancies as well. See related commentary by Bal and Costa, p. 10.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"38-54"},"PeriodicalIF":11.5,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Approvals Advancing Blood Cancer Medicine. 新批准推动血癌医学发展。
IF 11.5
Blood Cancer Discovery Pub Date : 2025-01-08 DOI: 10.1158/2643-3230.BCD-24-0300
{"title":"New Approvals Advancing Blood Cancer Medicine.","authors":"","doi":"10.1158/2643-3230.BCD-24-0300","DOIUrl":"10.1158/2643-3230.BCD-24-0300","url":null,"abstract":"<p><p>Recent advancements in clinical tools for blood cancers are highlighted in this article, adapted from the 14th edition of the annual AACR Cancer Progress Report (https://cancerprogressreport.aacr.org/progress/) to the US Congress and the public.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"5-9"},"PeriodicalIF":11.5,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142733074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acknowledgment to Reviewers. 感谢审稿人。
IF 11.5
Blood Cancer Discovery Pub Date : 2025-01-08 DOI: 10.1158/2643-3230.BCD-6-1-AR
{"title":"Acknowledgment to Reviewers.","authors":"","doi":"10.1158/2643-3230.BCD-6-1-AR","DOIUrl":"https://doi.org/10.1158/2643-3230.BCD-6-1-AR","url":null,"abstract":"","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":"6 1","pages":"73-74"},"PeriodicalIF":11.5,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信